Trending Content - Private Equity Forum
Career Resources
WSO Free Modeling Series - Now Open Through
November 30, 2026
9 Free Financial Modeling Lessons
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
+Bonus: Get 27 financial modeling templates in swipe file
+Bonus: Get 27 financial modeling templates in swipe file
High Finance Applications
Guaranteed
Get at least one offer GUARANTEED
- 1:1 support
- 92% success rate
- 2,000+ mentor network
- Unlimited Live bootcamps
- AI for resume + LinkedIn
- Networking automation tools
- HireVue simulation tool
- Full course library
- Private Slack community
- 20hrs of mocks
- + much more...
Biotech isn't really a space that a lot of mature PE firms play in. There may be some that do but that's more of a VC/growth play. On your second question, that would depend on what "better" means to you.
MM that are HC only: Altaris, Patient Square, Linden, Cressey, GHO. Lot of LMM funds, with a bunch in Chicago
UMM/MM with HC coverage: NMC, Genstar, GTCR, WCAS, Kohlberg, Audax, THL, Court Square, Nordic. Would also add GA, TA, Summit types of the world since they sometimes overlap in focus although they typically employ a bit of a different model given their growth angle
What about groups like Blackstone LS that formed after acquiring Clarus? Their work isn’t really VC per se right?
This isn't really PE in the traditional sense. Its more hybrid value-esque. Basically credit investments in late stage clinical or commercial stage biotechs along with some royalty investing and maybe some equity upside.
oh okay makes sense - so assuming that Bain cap life sciences is a similar model then? And so both of these "PE" groups don't rlly do any LBOs right (since cash flows are not stable enough from the acquisition targets)? If that's the case, do you think the carry received is still lucrative (like typical MFPE) based on their investment model?
Minus dignissimos in debitis expedita distinctio est eius nihil. Iste ex corporis perferendis asperiores dignissimos odit. Esse possimus nulla repudiandae commodi autem. Sed voluptas modi iusto quaerat. Totam voluptatum in aut tenetur. Tenetur voluptas quo aut sapiente. Aperiam saepe aut dolorem sapiente impedit. Dignissimos praesentium dolore officia qui dolorem.
Aperiam sit omnis alias possimus optio ut ad. Ad voluptates cupiditate nam reprehenderit. Dolore eaque qui reprehenderit voluptatem. Rerum aliquam totam et voluptate neque.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...